Microtubule-Stabilizing 1,2,4-Triazolo[1,5-a]pyrimidines as Candidate Therapeutics for Neurodegenerative Disease: Matched Molecular Pair Analyses and Computational Studies Reveal New Structure–Activity Insights
暂无分享,去创建一个
Virginia M. Y. Lee | A. Brancale | Amos B. Smith | C. Caffrey | K. Brunden | C. Ballatore | Goodwell Nzou | Anne-Sophie Cornec | Killian Oukoloff | Bobby Lucero | C. Varricchio | Yuemang Yao | T. Alle | Karol R. Francisco | Stefania Demuro | Megan Muench | Khoa D. Vuong
[1] S. Matthew,et al. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site , 2021, Proceedings of the National Academy of Sciences.
[2] J. Trojanowski,et al. Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. , 2021, Journal of medicinal chemistry.
[3] Yuquan Wei,et al. Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effect , 2020, Science Advances.
[4] J. Trojanowski,et al. Correction of microtubule defects within Aβ plaque‐associated dystrophic axons results in lowered Aβ release and plaque deposition , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[5] J. Trojanowski,et al. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model , 2018, Molecular Neurodegeneration.
[6] F. Bradke,et al. Systemic administration of epothilone D improves functional recovery of walking after rat spinal cord contusion injury , 2017, Experimental Neurology.
[7] M. Steinmetz,et al. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin. , 2017, Cell chemical biology.
[8] J. Trojanowski,et al. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy , 2016, Acta neuropathologica communications.
[9] J. Trojanowski,et al. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer’s Disease and Related Tauopathies , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[10] J. Trojanowski,et al. Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. , 2015, Bioorganic & medicinal chemistry letters.
[11] S. Minoshima,et al. Paclitaxel improves outcome from traumatic brain injury , 2015, Brain Research.
[12] J. Trojanowski,et al. Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies , 2014, Journal of medicinal chemistry.
[13] J. Trojanowski,et al. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.
[14] Nan Zhang,et al. Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition. , 2007, Journal of medicinal chemistry.
[15] Chi Li,et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[16] H. Bestmann,et al. An Improved One-pot Procedure for the Synthesis of Alkynes from Aldehydes , 1996 .